| Literature DB >> 22449203 |
Satish Srinivas Kitambi1, Erik S Nilsson, Petra Sekyrova, Cristian Ibarra, Gilbert Nyah Tekeoh, Michael Andäng, Patrik Ernfors, Per Uhlén.
Abstract
BACKGROUND: Cardiovascular toxicity is a major limiting factor in drug development and requires multiple cost-effective models to perform toxicological evaluation. Zebrafish is an excellent model for many developmental, toxicological and regenerative studies. Using approaches like morpholino knockdown and electrocardiogram, researchers have demonstrated physiological and functional similarities between zebrafish heart and human heart. The close resemblance of the genetic cascade governing heart development in zebrafish to that of humans has propelled the zebrafish system as a cost-effective model to conduct various genetic and pharmacological screens on developing embryos and larvae. The current report describes a methodology for rapid isolation of adult zebrafish heart, maintenance ex vivo, and a setup to perform quick small molecule throughput screening, including an in-house implemented analysis script.Entities:
Mesh:
Year: 2012 PMID: 22449203 PMCID: PMC3334682 DOI: 10.1186/1472-6793-12-3
Source DB: PubMed Journal: BMC Physiol ISSN: 1472-6793
Figure 1A) Whole heart, isolated from wild type adult zebrafish showing Atrium (abbreviated: at) and Ventricle (abbreviated: v). B) Petri dish with embedded hearts used for screening. C) Diagrammatical representation of the screening setup. Petri dish with embedded hearts is placed on an inverted microscope having an in- and out-let to regulate the in- and out-flow of fresh Krebs buffer. D) Analyses of heartbeating using MATLAB. E) Three hearts mounted on a Petri dish to measure Ca2+ responses. The regions of interest (ROI1 and ROI2) that were used to analyze Ca2+ responses are shown with blue and red circles. F) Graph showing spontaneous Ca2+ activity and compound-induced Ca2+ response in ROI1 (in blue) and ROI2 (in red). Analyses of heartbeats at 28°C G) and 37°C H). Analyses of heartbeats obtained from screen of compounds as indicated carried out at 28°C I) and 37°C J). Compound concentrations of 10 μM were used in the screen. Scale bar: 200 μm in A.
Figure 2A) Flowchart showing the screening procedure to assess compounds. B-I) Spectral analyses of heartbeats from hearts treated with various compounds. Spectra from control (DMSO) treatments or untreated hearts are shown in blue, while spectra from compound exposures are shown in red. B-C) Spectra from hearts treated with two different concentrations, as indicated, of clofilium. Spectra from hearts treated with different Ca2+ channel modulators D-E), chloride transport inhibitors F-H) and blebbistatin I). Compound concentrations of 10 μM were used in the screen. Data shown in panels B-D, E-G and H-L were generated by three separate screening.
Figure 3Spectral analyses of the beating efficiency of immortalized HL-1 cardiomyocytes after exposure to DMSO (A), clofilium (B) and blebbistatin (C). Compound concentrations of 1 μM were used in the screen.